| Immunocellular Therapeutics' Brain Cancer Vaccine Extends Survival Rate in Small Trial Douglas Cress submits:By vandersonA brain cancer vaccine from Immunocellular Therapeutics (IMUC.OB) has yielded positive results in a small Phase I clinical trial, reports Fierce Biotech. The study involved only 16 patients with glioblastoma multiforme, the most common form of brain cancer. The patients received the ICT-107 vaccine in combination with conventional treatments such as surgery and chemotherapy. Half of the group remained alive at 18 months with no progression of the disease, and 7 out of 16 patients remain alive with no disease progression at an average of 29 months. The overall patient survival rate was 100 percent at one year and 80 percent at two years, compared to a historical survival rate with standard therapy of 61.1 percent at one year and 26.5 percent at two years. ICT-107 is a dendritic cell-based vaccine that uses the patient’s own cells to provoke a disease-fighting response.Complete Story » seekingalpha.com |
Earnings Preview: Celgene theflyonthewall.com submits: Celgene (CELG) is expected to report Q2 earnings Thursday, July 29 before the market open, with a conference call scheduled for 9 am ET. GuidanceAnalysts are looking for EPS of 66c on revenue of $820.4M. The consensus range is 64c-70c for EPS, and $781.5M-$841M for revenue, according to First Call. Possible positives for Celgene's Q2 results should come from Revlimid and Vidaza sales. Vidaza was recently approved in Europe. Negative factors that may effect this quarter include slower Revlimid sales and the fallout from health care reform. Complete Story » seekingalpha.com |
FDA to Give Priority Review to Melanoma Drug Bristol-Myers Squibb said the FDA agreed to give a priority review to its experimental advanced melanoma treatment, ipilimumab. online.wsj.com |
ImmunoCellular Therapeutics CEO Explains Economic Significance of New Vaccine Manufacturing Method M.E. Garza submits: On Wednesday morning, ImmunoCellular Therapeutics (IMUC.OB) announced that it has developed an innovative method for manufacturing the company’s dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM). Given all the headlines that Dendreon (Nasdaq:DNDN) has made with its manufacturing problems, IMUC's lead product candidate, ICT-107, may well start making news of its own. DNDN's Provenge won FDA approval last April, but sales have been hindered by the company's limited production capacity, an issue which DNDN management has said it expects to resolve some time next year.Complete Story » seekingalpha.com |
China Cord Blood Corporation Reports Second Quarter and First Half Fiscal 2011 Financial Results [PR Newswire] - China Cord Blood Corporation , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the second quarter and first half of fiscal 2011 ended September 30, 2010. us.rd.yahoo.com |